Safety and Efficacy of a Beverage Containing Lupine Protein Hydrolysates on the Immune, Oxidative and Lipid Status in Healthy Subjects: An Intervention Study (the Lupine‐1 Trial)

• Published in: Molecular nutrition & food research Vol. 65; no. 14; pp. e2100139 - n/a
• Main Authors: Cruz‐Chamorro, Ivan, Álvarez‐Sánchez, Nuria, Álvarez‐Ríos, Ana Isabel, Santos‐Sánchez, Guillermo, Pedroche, Justo, Millán, Francisco, Carrera Sánchez, Cecilio, Fernández‐Pachón, María Soledad, Millán‐Linares, María Carmen, Martínez‐López, Alicia, Lardone, Patricia Judith, Bejarano, Ignacio, Guerrero, Juan Miguel, Carrillo‐Vico, Antonio
• Format: Journal Article
• Language: English
• Published: Germany Wiley Subscription Services, Inc 01.07.2021
• Subjects: Adult; Antioxidants; Antioxidants - metabolism; Arteriosclerosis; Atherosclerosis; Beverages; Biomarkers - blood; Blood; blood serum; Cardiovascular diseases; Cholesterol; cholesterol metabolism; Cholesterol, HDL - blood; Cholesterol, LDL - blood; clinical trials; Cytokines - metabolism; Density; Female; food research; functional foods; Functional foods & nutraceuticals; Health risks; health status; Healthy Volunteers; High density lipoprotein; Humans; hydrolysate; Hydrolysates; Inflammation; Inflammatory response; Ingestion; Kidney; Leukocytes (mononuclear); Leukocytes, Mononuclear - drug effects; Lipid metabolism; Lipids; Lipids - blood; Liver; Longitudinal Studies; Low density lipoprotein; lupine; Lupinus - chemistry; Lupinus angustifolius; Male; males; nutrition; Oxidants; Oxidative metabolism; Oxidative stress; Oxidative Stress - drug effects; Oxidizing agents; Peptides; Peripheral blood mononuclear cells; Protein Hydrolysates - pharmacology; Proteins; Risk analysis; Risk factors; Safety; urine; cholesterol; lupine; hydrolysate; inflammation; oxidative stress
• ISSN: 1613-4125; 1613-4133; 1613-4133
• DOI: 10.1002/mnfr.202100139

Scope We have previously demonstrated the anti‐inflammatory and antioxidant properties of in vitro administered Lupinus angustifolius protein hydrolysates (LPHs) on human peripheral blood mononuclear cells (PBMCs). This study aims to evaluate the safety and efficacy of a beverage containing LPHs (LPHb) on the immune, oxidative and metabolic status of healthy subjects. Methods and Results In this open‐label intervention, 33 participants daily ingest a LPHb containing 1 g LPHs for 28 days. Biochemical parameters are assayed in fasting peripheral blood and urine samples before, during (14 days) and after LPHb ingestion. Participants’ health status and the immune and antioxidant responses of PBMCs are also evaluated throughout the trial. The LPHb ingestion is safe and effective in both increasing the anti‐/pro‐inflammatory response of PBMCs and improving the cellular anti‐oxidant capacity. LPHb also reduces the low‐density lipoprotein‐cholesterol (LDL‐C)/high‐density lipoprotein‐cholesterol (HDL‐C) atherogenic index. LPHb effect is particularly beneficial on decreasing not only the LDL‐C/HDL‐C index but also serum total cholesterol levels in the male cohort that shows the highest baseline levels of well‐known cardiovascular risk factors. Conclusion This is the first study to show the pleiotropic actions of a lupine bioactive peptides‐based functional food on key steps of atherosclerosis including inflammation, oxidative stress, and cholesterol metabolism. The intake of a functional beverage based on Alcalase 2.4 L‐generates lupine protein hydrolysates for 28 days which increases the anti‐inflammatory microenvironment, as well as the cellular antioxidant capacity in healthy subjects. In addition, the intake of this beverage reduces the LDL‐C/HDL‐C atherogenic index.